The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile-Reference-Cited by-同舟云学术

The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile

Published:2011-04-19 Issue:9 Volume:71 Page:3189-3195
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Eide Christopher A.,Adrian Lauren T.,Tyner Jeffrey W.,Mac Partlin Mary,Anderson David J.,Wise Scott C.,Smith Bryan D.,Petillo Peter A.,Flynn Daniel L.,Deininger Michael W.N.,O'Hare Thomas,Druker Brian J.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells;Journal of Interferon & Cytokine Research;2024-04-01

2. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia;International Journal of Molecular Sciences;2024-03-14

3. Design, Synthesis, and Molecular Docking Studies of New Quinoline-Thiazole Hybrids, Potential Leads in the Development of Novel Antileukemic Agents;Journal of the Brazilian Chemical Society;2024

4. Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors;Medical Oncology;2023-07-13

5. Ruscogenin ameliorates dasatinib-induced intestinal barrier dysfunction via ErbB4/YAP and ROCK/MLC pathways;Journal of Natural Medicines;2023-06-22